High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population
Advancements in next-generation sequencing have facilitated tumour-agnostic approaches for cancer therapy. Here, we demonstrate the clinical utility of molecularly guided tumour-agnostic precision medicine in an Asian cohort, leveraging an Asian-centric DNA/RNA comprehensive genomic profiling (CGP) panel. A total of 1166 tissue samples encompassing 29 cancer types underwent real-world CGP testing. Actionable biomarkers were identified in 62.3% of samples, including 1291 (4.7%) somatic variants potentially targetable by regulatory-approved therapies. At least one tumour-agnostic biomarker, including high tumour mutation burden (TMB-high), microsatellite instability (MSI-high), NTRK/RET fusions, and BRAF V600E was identified in 98 samples across 26 cancer types (8.4%). ERBB2 amplification was identified in 42 samples (3.6%) and was most frequently detected in breast (15.0%), followed by endometrial (11.8%) and ovarian tumours (8.9%). Homologous recombination deficiency (HRD) was observed in 407 samples (34.9%). The high prevalence of actionable biomarkers underscores the significance of CGP in facilitating precision medicine in an Asian setting.
Authors
- Zi Yi Wan (ORCID: https://orcid.org/0000-0001-5862-7816)
- Su Pin Choo (ORCID: https://orcid.org/0000-0002-8925-3922)
- Ross Andrew Soo (ORCID: https://orcid.org/0000-0002-3053-3997)
- Joseph S. K. Au (ORCID: https://orcid.org/0009-0000-2021-3650)
- Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
- Bin Tean Teh (ORCID: https://orcid.org/0000-0003-1514-1124)
- Jens Samol (ORCID: https://orcid.org/0000-0001-6109-3528)
- Ruifen Weng
- Aya El Helali (ORCID: https://orcid.org/0000-0001-6427-114X)
- Daniel S.W. Tan (ORCID: https://orcid.org/0000-0002-6514-6786)
- Jonathan Poh (ORCID: https://orcid.org/0000-0003-0114-8667)
- Cheng-Vai Hui
- Jing Yi Lee (ORCID: https://orcid.org/0009-0005-0650-9339)
- Jason Yongsheng Chan
- Timothy T. C. Yip
- Min-Han Tan
- Michelle Pek
- Donald Poon
- Tsz Him So
Institutions
- Agency for Science, Technology and Research (SG)
- Johns Hopkins University (US)
- Tan Tock Seng Hospital (SG)
- Mount Elizabeth Novena Hospital (SG)
- National University Cancer Institute, Singapore (SG)
- Hong Kong Design Centre (CN)
- Experimental Drug Development Centre (SG)
- Society of Hong Kong Scholars (CN)
- National Cancer Centre Singapore (SG)
- Hospital Conde S. Januário (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- npj Precision Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1038/s41698-025-01126-x
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Duke-NUS Medical School
- Medical Research Council
- National Medical Research Council